… -1 protein (PD)-L1-positive advanced non-… analysis compared outcomes in patients based
on PD-L1 expression in archival versus newly collected tumor samples using recently updated …

… We report an updated analysis of OS and other efficacy and safety outcomes after a median
follow-up of 25.2 months. In addition, we describe outcomes among patients who crossed …

… ) suggested that the PD-1 inhibitor pembrolizumab has promising antitumor activity in pts
with PD-L1 + advanced ovarian cancer. An updated analysis of the ovarian cancer cohort …

… However, whether PD-L1 expression is a prognostic factor for … role of PD-L1 expression
through a meta-analysis update of … -analysis suggest the correlation of PD-L1 overexpression …

… is PD-L1 expression, its clinical significance is still debatable. In this article, we show the
updated survival analysis … study update is to assess the survival according to PD-L1 expression. …

… preplanned updated OS analysis … Updated analyses of safety and OS by blood-based tumor
mutational burden (bTMB) levels, as well as exploratory analyses of OS according to PD-L1 …

… treatment with the anti‒PD-1 antibody pembrolizumab … PD-L1 tumor proportion score (TPS)≥
50% and without EGFR mutations or ALK translocations. Results from the primary analysis …

… This meta-analysis systematically evaluated the efficacy and safety of anti-PD-1/PD-L1
antibodies for … More importantly, the results of this meta-analysis suggested that anti-PD-1/PD-L1 …

… At the final OS analysis, IMpower110 did not show statistical significance in TC2/3 or IC2/3-WT
patients. Exploratory updated analysis in TC3 or IC3-WT patients showed continued …

… analyses in lower PD-L1 expression groups and an updated, … updated analysis of IMpower110
supports using atezolizumab in treatment-naive, metastatic WT NSCLC with high PD-L1 …